• AG-221 (Enasidenib): Targeted IDH2 Inhibition in AML Researc

  2026-07-09

  AG-221 (Enasidenib) is a selective inhibitor of mutant IDH2 used in acute myeloid leukemia (AML) research. It potently reduces 2-hydroxyglutarate, reverses epigenetic dysregulation, and induces cell differentiation in IDH2-mutant models. Phase 1 trials show safety and measurable efficacy for hematologic malignancies with IDH2 mutations.

• Ectomesenchymal Stem Cells Modulate Microglia After Brain He

  2026-07-08

  This study demonstrates that transplantation of nasal mucosa-derived ectomesenchymal stem cells (EMSCs) after intracerebral hemorrhage (ICH) in mice shifts microglia toward an anti-inflammatory phenotype and enhances IL-10 secretion by inhibiting NF-κB and MAPK pathways. These mechanistic insights clarify how EMSCs mitigate neuroinflammation and suggest their promise as a therapeutic avenue for hemorrhagic stroke.

• Trypsin-Responsive Nanomedicine for Targeted Acute Pancreati

  2026-07-08

  This study presents a biomimetic, trypsin-cleavable mesoporous organosilica nanomedicine that enables precise, cell-targeted delivery of a calcium chelator for the treatment of acute pancreatitis. Leveraging trypsin’s pathological role and cell membrane-coating strategies, the approach restores pancreatic function and significantly improves survival in preclinical models.

• NF 340 (SKU B7508): Scenario-Driven Solutions for P2Y11 Anta

  2026-07-07

  This article presents evidence-based best practices for using NF 340 (SKU B7508), a selective P2Y11 antagonist, in cell viability, proliferation, and cytotoxicity assays. Drawing on recent literature and real laboratory scenarios, it demonstrates how NF 340 supports reproducible, data-driven workflows in biomedical research. Practical guidance helps ensure optimal assay performance and reliability.

• Erastin as a Ferroptosis Inducer: Expanding Horizons in Canc

  2026-07-07

  Discover how Erastin, a leading ferroptosis inducer, transforms cancer biology and vascular research by enabling precise manipulation of iron-dependent cell death pathways. This article provides a deep dive into its mechanisms, protocol optimization, and the latest cross-disciplinary insights.

• PDHA1 Succinylation Drives Immune Escape in Cholangiocarcino

  2026-07-06

  This study uncovers how succinylation of PDHA1 at lysine 83 in cholangiocarcinoma orchestrates a metabolic-immune axis that enables immune escape. By elucidating the link between altered TCA cycle flux, alpha-ketoglutaric acid accumulation, and suppressed macrophage antigen presentation, the findings highlight new therapeutic opportunities to overcome chemotherapy resistance.

• 1-myristoylglycerophosphocholine: Unveiling Lipid Signaling

  2026-07-06

  Explore how 1-myristoylglycerophosphocholine empowers advanced lipid signaling research and smooth muscle studies. This article uniquely translates mechanistic insights from recent fibrosis research into practical assay optimization and protocol guidance.

• HIV-1 Remodels T Cell Nuclear Pores for Infection via CD4-LC

  2026-07-05

  This study uncovers how HIV-1 overcomes the intrinsic resistance of resting CD4+ T cells by remodeling the nuclear pore complex (NPC) through cell–cell contact signaling. The findings highlight a critical role for CD4-LCK-CDK1 signaling in licensing infection, redefining our understanding of HIV-1 pathogenesis and T cell susceptibility.

• KX2-391 Dihydrochloride: Translational Leverage for Oncology

  2026-07-04

  Explore the dual-action mechanistic landscape of KX2-391 dihydrochloride (Tirbanibulin dihydrochloride) and its strategic value for translational researchers in oncology, virology, and neurotoxin biology. This thought-leadership article synthesizes new mechanistic insights, practical workflow parameters, and cross-domain guidance, empowering the next generation of pathway-centric drug discovery.

• Muscle-Derived BDNF Shapes Initial NMJ Postsynaptic Assembly

  2026-07-03

  This study reveals that muscle-generated BDNF, through spatially localized trafficking and proteolytic conversion, orchestrates the initial formation of postsynaptic acetylcholine receptor clusters at neuromuscular junctions. The findings clarify the molecular and spatial mechanisms of early synaptic assembly, advancing experimental approaches to dissect muscle-neuron communication.

• Gramine Induces Ferroptosis in TNBC via CUL3–MTDH Ubiquitina

  2026-07-03

  The referenced study establishes Gramine as a selective ferroptosis inducer in triple-negative breast cancer (TNBC) by targeting the CUL3–MTDH ubiquitination axis. This mechanistic insight positions Gramine as a promising tool for dissecting ferroptosis and ubiquitination pathways in cancer biology research.

• Next-Gen Reporter Assays: Deep Dive into EZ Cap EGFP mRNA 5-

  2026-07-02

  Explore how EZ Cap EGFP mRNA 5-moUTP advances enhanced green fluorescent protein mRNA reporter studies with unmatched stability and translational efficiency. This article uniquely analyzes the interplay of immune modulation and targeted delivery in modern assay design.

• Tetrahedral DNA Frameworks Enhance Enzymatic Oligonucleotide

  2026-07-02

  A recent study demonstrates that highly ordered tetrahedral DNA nanostructures (TDN) significantly improve enzymatic oligonucleotide synthesis (EOS) by optimizing primer orientation and enzyme accessibility. This breakthrough reduces synthesis errors and increases DNA yield, offering promising advances for DNA data storage and molecular probe development.

• AICAR Phosphate: AMPK Activation & Apoptosis Mechanisms

  2026-07-01

  AICAR phosphate (Acadesine) is a potent AMPK activator and apoptosis inducer. It selectively induces programmed cell death in B-cell chronic lymphocytic leukemia (B-CLL) cells. The compound’s mechanistic specificity and solubility profile position it as a valuable tool in cancer research and mitochondrial biology.

• Azathramycin A: Macrolide Antibiotic for Tuberculosis Models

  2026-07-01

  Azathramycin A is a macrolide antibiotic that inhibits Mycobacterium tuberculosis ribosomes, disrupting bacterial protein synthesis. It is primarily used as an antibacterial agent for tuberculosis research. As a validated impurity and degradation product of azithromycin, Azathramycin A enables mechanistic studies of antibiotic resistance and protein synthesis inhibition.

453 records 12/31 page Previous Next First page 上5页 1112131415 下5页 Last page